Enter your information to understand your apolipoprotein b levels.

The History of ApoB

ApoB's history traces back to physician and scientist John Gofman, who in the early 1950s at the University of California, Berkeley, used high-speed ultracentrifugation to separate blood fat particles by density, first identifying the LDL and VLDL classes that ApoB would later be found riding inside as their structural backbone. As protein chemistry techniques matured through the 1960s and 1970s, researchers identified ApoB as the single structural protein embedded in every LDL and VLDL particle, present in exactly one copy no matter the particle's overall size or cholesterol content at any point. Then, in 1987, two independent research teams made a remarkable discovery: the body actually produces two different versions of this protein from the very same underlying gene, using a unique form of genetic editing in the intestine that had never before been observed anywhere in human biology at that point in time, surprising molecular biologists everywhere who studied it closely.

What ApoB Actually Is

ApoB is the primary structural protein carried by LDL and VLDL particles — the lipoproteins most strongly linked to plaque buildup inside artery walls over many years — and critically, each individual particle carries exactly one molecule of ApoB, regardless of how much cholesterol that particular particle happens to be carrying at any given moment in time. This makes ApoB a direct measurement of the actual number of potentially artery-clogging particles circulating in the blood, rather than the total cholesterol content spread unevenly across them, which is why many cardiologists now consider it a more precise cardiovascular risk marker than a standard LDL cholesterol result taken by itself. The liver produces the larger form, called ApoB-100, while the intestine produces a distinctly shorter version known as ApoB-48.

How ApoB Is Measured

Laboratories measure ApoB using immunoturbidimetric or immunonephelometric assays, in which antibodies designed specifically to bind ApoB are mixed with a patient's blood sample, forming small clusters that scatter light in proportion to how much protein is actually present in that particular sample being tested that day. An automated analyzer detects and precisely quantifies this light scattering in real time, producing a numeric result calibrated against international reference standards to keep results broadly consistent across different laboratories and testing equipment used worldwide, year after year, regardless of manufacturer or country of origin.

Scientists Behind the Science

John Gofman's early ultracentrifugation work laid the essential groundwork for identifying the lipoprotein particles that ApoB would eventually be found within decades later, once analytical chemistry techniques finally caught up. The 1987 discovery of ApoB's unusual genetic editing process, published independently and almost simultaneously by two separate research groups, revealed that a single gene could be edited differently depending on which organ in the body was reading it, a finding that reshaped scientists' broader understanding of gene expression far beyond cholesterol research alone. That discovery remains one of molecular biology's most striking examples of how one single genetic blueprint can produce two functionally distinct proteins entirely, each one tailored precisely to its own specific organ.